Tekmira Pharmaceuticals Corp. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 48

Tekmira Pharmaceuticals Corp. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Tekmira Pharmaceuticals Corp. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Tekmira Pharmaceuticals Corp. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Tekmira Pharmaceuticals Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Tekmira Pharmaceuticals Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Tekmira Pharmaceuticals Corp.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Tekmira Pharmaceuticals Corp.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Tekmira Pharmaceuticals Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Tekmira Pharmaceuticals Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Tekmira Pharmaceuticals Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Tekmira Pharmaceuticals Corp. and identify potential opportunities in those areas.

List of Tables
List of Figures
Tekmira Pharmaceuticals Corp. Snapshot
Tekmira Pharmaceuticals Corp. Overview
Key Information
Key Facts
Tekmira Pharmaceuticals Corp. – Research and Development Overview
Key Therapeutic Areas
Tekmira Pharmaceuticals Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Tekmira Pharmaceuticals Corp. – Pipeline Products Glance
Tekmira Pharmaceuticals Corp. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Tekmira Pharmaceuticals Corp.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Tekmira Pharmaceuticals Corp. – Drug Profiles
ApoB SNALP
Product Description
Mechanism of Action
R&D Progress
PLK1 SNALP
Product Description
Mechanism of Action
R&D Progress
RNAi candidates
Product Description
Mechanism of Action
R&D Progress
TKM-PLK1
Product Description
Mechanism of Action
R&D Progress
Tekmira Pharmaceuticals Corp. – Pipeline Analysis
Tekmira Pharmaceuticals Corp. – Pipeline Products by Therapeutic Class
Tekmira Pharmaceuticals Corp. Pipeline Products By Target
Tekmira Pharmaceuticals Corp. – Pipeline Products by Molecule Type
Tekmira Pharmaceuticals Corp. – Recent Pipeline Updates
Tekmira Pharmaceuticals Corp. – Company Statement
Tekmira Pharmaceuticals Corp. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 10, 2010: Tekmira Delays Initiation Of Next TKM-ApoB Clinical Trial
Sep 10, 2010: Tekmira Plans To Expand Development Of TKM-PLK1 In Collaboration With NCI
Sep 10, 2010: Tekmira Initiates Development Of TKM-Ebola
Sep 07, 2010: Tekmira Receives FDA Clearance To Initiate TKM-PLK1 Phase I Clinical Trial
Aug 05, 2010: Tekmira Files PLK1 SNALP IND Application With FDA For Treatment Of Solid Tumor Cancers
Feb 24, 2010: Tekmira Presents ApoB SNALP Data At AsiaTIDES RNAi Scientific Conference
Jan 07, 2010: Tekmira Pharmaceuticals Completes Phase 1 Clinical Trial Of ApoB SNALP
Jul 02, 2009: Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
May 28, 2009: Tekmira Pharmaceuticals Presents ApoB SNALP Data At Leading Scientific Conference
May 07, 2009: Tekmira Pharmaceuticals Receives Clearance From FDA To Initiate ApoB SNALP Phase 1 Clinical Trial
Financial Deals Landscape
Tekmira Pharmaceuticals Corp., Deals Volume Summary, 2004 to YTD 2010
Tekmira Pharmaceuticals Corp., Deals Summary By Region, 2004 to YTD 2010
Tekmira Pharmaceuticals Corp., Deals Summary, 2004 to YTD 2010
Tekmira Pharmaceuticals Corp. Detailed Deal Summary
Merger
Tekmira Pharmaceuticals Merges With Protiva Biotherapeutics
Equity Offering
Tekmira Completes Private Placement Of $5 Million With Alnylam
Alnylam Pharmaceuticals Enters Into Agreement With Tekmira Pharmaceuticals
Tekmira Pharmaceuticals Enters Into Co-Development Agreement With Roche
Bristol-Myers Squibb Extends Research Agreement With Tekmira Pharmaceuticals
Tekmira Enters Into Research Agreement With Takeda Pharmaceuticals
Bristol-Myers Squibb Enters Into Co-Development Agreement With Tekmira Pharmaceuticals
Tekmira Amends Research Collaboration With Alnylam Pharmaceuticals
Licensing Agreements
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Tekmira Pharmaceutical
Merck Enters Into Licensing Agreement With Protiva Biotherapeutics
Hana Biosciences Enters Into Licensing Agreement With Inex Pharmaceuticals
Tekmira Pharmaceuticals Enters Into Licensing Agreement With Aradigm
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Sports and Fitness Nutrition - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Aerospace and Defense Industry - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Charter Schools - Global Outlook
• Analysis of the Contact Center Applications Market
• Aerospace and Defence Industry - Global Strategic Business Report